Subsequent clinical success demonstrated that these liabilities could be mitigated through slower absorption kinetics, extended dosing intervals, and careful titration, ultimately allowing the beneficial metabolic effects to dominate the riskbenefit profile (Drucker, 2018
Understanding how GLP-1 medications relate to the broader peptide landscape helps contextualize your research
Published in the New England Journal of Medicine, the trial tested retatrutide at doses of 1mg, 4mg, 8mg, and 12mg against placebo over 48 weeks
Questions to raise include whether the trial is legitimate, which condition it studies, what visits are required, what monitoring is included, and how adverse effects are handled